Terms: = Breast cancer AND CARS, P49589, 833, ENSG00000110619 AND Treatment
103 results:
1. Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.
Wang Y; Li Y; Jiang H; Zuo C; Xu W
Br J Radiol; 2024 Jan; 97(1153):237-248. PubMed ID: 38263821
[TBL] [Abstract] [Full Text] [Related]
2. Endogenous Signaling Molecule Activating (ESMA) cars: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the treatment of Triple Negative breast cancer.
Ebbinghaus M; Wittich K; Bancher B; Lebedeva V; Appelshoffer A; Femel J; Helm MS; Kollet J; Hardt O; Pfeifer R
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203786
[TBL] [Abstract] [Full Text] [Related]
3. Quality of Life in breast cancer Patients Treated With Mistletoe Extracts: A Systematic Review and Meta-Analysis.
Loef M; Paepke D; Walach H
Integr Cancer Ther; 2023; 22():15347354231198074. PubMed ID: 37888846
[TBL] [Abstract] [Full Text] [Related]
4. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
Int J Cancer; 2024 Feb; 154(4):701-711. PubMed ID: 37831416
[TBL] [Abstract] [Full Text] [Related]
5. Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review).
Kausar MA; Anwar S; El-Horany HE; Khan FH; Tyagi N; Najm MZ; Sadaf ; Eisa AA; Dhara C; Gantayat S
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37830150
[TBL] [Abstract] [Full Text] [Related]
6. A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line treatment With Monotherapy in Advanced Non-small Cell Lung cancer With Epidermal Growth Factor Receptor Mutation.
Zhao KX; Zhang YF; Zheng L; Pan YF; He ZH
Am J Clin Oncol; 2023 Dec; 46(12):551-558. PubMed ID: 37779240
[TBL] [Abstract] [Full Text] [Related]
7. Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy.
Jin Y; Lan A; Dai Y; Jiang L; Liu S
Eur J Med Res; 2023 Sep; 28(1):394. PubMed ID: 37777809
[TBL] [Abstract] [Full Text] [Related]
8. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative breast cancer Cells as Shown in Several Preclinical Models.
Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
[TBL] [Abstract] [Full Text] [Related]
9. Voluntary Deep Inspiration Breath-Hold (VDIBH) Whole-breast Irradiation Assisted by Optical Surface Monitoring System (OSMS) in Patients With Left-Sided breast cancer: A Prospective Phase II Study.
Zhang JH; Li TT; Qin SR; Liu ZQ; Chen SY; Song YW; Tang Y; Jing H; Fang H; Zhao XR; Jin J; Liu YP; Tang Y; Qi SN; Li N; Chen B; Lu NN; Li YX; Wang SL
Technol Cancer Res Treat; 2023; 22():15330338231173773. PubMed ID: 37312511
[No Abstract] [Full Text] [Related]
10. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative breast cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
[TBL] [Abstract] [Full Text] [Related]
11. Advances in natural killer cell therapies for breast cancer.
Kiaei SZF; Nouralishahi A; Ghasemirad M; Barkhordar M; Ghaffari S; Kheradjoo H; Saleh M; Mohammadzadehsaliani S; Molaeipour Z
Immunol Cell Biol; 2023 Sep; 101(8):705-726. PubMed ID: 37282729
[TBL] [Abstract] [Full Text] [Related]
12. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report.
Wang Y; Zhao Y; Li M; Hou H; Jian Z; Li W; Li P; Ma F; Liu M; Liu H; Xue H
Front Immunol; 2023; 14():1180001. PubMed ID: 37256142
[TBL] [Abstract] [Full Text] [Related]
13. Synthesis of 3-(2-Alkylthio-4-chloro-5-methylbenzenesulfonyl)-2-(1-phenyl-3-arylprop-2-enylideneamino)guanidine Derivatives with Pro-Apoptotic Activity against cancer Cells.
Pogorzelska A; Sławiński J; Kawiak A; Stasiłojć G; Chojnacki J
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901869
[TBL] [Abstract] [Full Text] [Related]
14. Association of Anthracycline With Heart Failure in Patients Treated for breast cancer or Lymphoma, 1985-2010.
Larsen CM; Garcia Arango M; Dasari H; Arciniegas Calle M; Adjei E; Rico Mesa J; Scott CG; Thompson CA; Cerhan JR; Haddad TC; Goetz MP; Herrmann J; Villarraga HR
JAMA Netw Open; 2023 Feb; 6(2):e2254669. PubMed ID: 36735254
[TBL] [Abstract] [Full Text] [Related]
15. HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
Kada Mohammed S; Billa O; Ladoire S; Jankowski C; Desmoulins I; Poillot ML; Coutant C; Beltjens F; Dabakuyo S; Arnould L
Breast Cancer; 2023 May; 30(3):343-353. PubMed ID: 36715845
[TBL] [Abstract] [Full Text] [Related]
16. Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive breast cancer Brain Metastases.
Jenkins S; Zhang W; Steinberg SM; Nousome D; Houston N; Wu X; Armstrong TS; Burton E; Smart DD; Shah R; Peer CJ; Mozarsky B; Arisa O; Figg WD; Mendoza TR; Vera E; Brastianos P; Carter S; Gilbert MR; Anders CK; Connolly RM; Tweed C; Smith KL; Khan I; Lipkowitz S; Steeg PS; Zimmer AS
Clin Cancer Res; 2023 Apr; 29(8):1450-1459. PubMed ID: 36705597
[TBL] [Abstract] [Full Text] [Related]
17. The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells.
Bakadlag R; Limniatis G; Georges G; Georges E
BMC Cancer; 2023 Jan; 23(1):24. PubMed ID: 36609245
[TBL] [Abstract] [Full Text] [Related]
18. Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy.
Franke AK; Wessolowski C; Thaden V; Müller I; Cornils K
Gene Ther; 2023 Aug; 30(7-8):603-611. PubMed ID: 36529796
[TBL] [Abstract] [Full Text] [Related]
19. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative breast cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
Sammons S; Raskina K; Danziger N; Alder L; Schrock AB; Venstrom JM; Knutson KL; Thompson EA; McGregor K; Sokol E; Chumsri S
JCO Precis Oncol; 2022 Oct; 6():e2200149. PubMed ID: 36315915
[TBL] [Abstract] [Full Text] [Related]
20. Beneficial Effects of Mifepristone treatment in Patients with breast cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.
Elía A; Saldain L; Vanzulli SI; Helguero LA; Lamb CA; Fabris V; Pataccini G; Martínez-Vazquez P; Burruchaga J; Caillet-Bois I; Spengler E; Acosta Haab G; Liguori M; Castets A; Lovisi S; Abascal MF; Novaro V; Sánchez J; Muñoz J; Belizán JM; Abba MC; Gass H; Rojas P; Lanari C
Clin Cancer Res; 2023 Mar; 29(5):866-877. PubMed ID: 36269797
[TBL] [Abstract] [Full Text] [Related]
[Next]
